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Pancreatic cancerThis study was aimed to investigate miR-216a expression in pancreatic cancer and determine its
effects on proliferation. miR-216a was found downregulated in pancreatic cancer tissues as
compared to benign pancreatic lesions. JAK2 was identiﬁed as a miR-216a gene target. Further,
in vivo treatment of PANC-1 tumors with miR-216a reduced JAK2 protein levels in the tumor and
reduced tumor volume. In conclusion, miR-216a may function as a tumor suppressor regulating
pancreatic cancer cells by targeting the JAK/STAT pathway. Further studies with a larger number
of patient samples are necessary to fully explore the diagnostic and therapeutic potential of
miR-216a for pancreatic cancer.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction as invasion andmetastasis [4]. For instance, Scholz et al. [5] demon-Pancreatic cancer is the fourth leading cause of cancer death
worldwide [1]. In China, it is the sixth commonest cause of
cancer-related mortality [2]. Pancreatic ductal adenocarcinoma
(PDAC) is the most common tumor type of the exocrine pancreas,
accounting for 85–90% for all of pancreatic tumors. Its late clinical
presentation, aggressive nature, and the lack of sensitivity to most
treatment options renders the mortality rate virtually equal to its
incidence with an overall 5-year survival rate of 6% and a median
survival rate approximately 5–6 months [3]. Therefore, identiﬁca-
tion of novel diagnostic markers and therapeutic targets is crucial.
Previous studies have demonstrated that the Janus kinase/signal
transducers and activators of transcription (JAK/STAT) pathway
may play an important role in pancreatic cancer progression as wellstrated aberrant activation of STAT3 in pancreatic cancer tissues
and cell lines. In addition, constitutive activation of STAT3 induced
cellular transformation and promoted pancreatic tumorigenesis,
possibly through regulating the expressions of target genes, such
as c-Myc, Bcl-xL, p21WAF1, cyclinD1 and VEGF [6], and its inhibition
led to growth arrest [7]. Conversely, functional inactivation of
STAT3 by dominant-negative STAT3 or AG490 inhibited the prolif-
eration and promoted the apoptosis of pancreatic cancer cells [6].
Along with the JAK/STAT pathway, abnormal expression of
microRNAs (miRNAs), non-coding single-stranded RNAs of approx-
imately 20–25 nucleotides in length that regulate gene expression
at the transcriptional or post-transcriptional level [8], has been
implicated in the oncogenic process as both oncogenes and tumor
suppressors. Moreover, approximately 50% of miRNAs are located
at or close to fragile sites of regions known to be ampliﬁed or
deleted in human cancer [9], and aberrant miRNA expression or
miRNA gene mutation have been well described in leukemia as
well as solid tumors, including pancreatic cancer [10–13]. In addi-
tion to regulating development, differentiation, apoptosis, prolifer-
ation, and viral infection [12], miRNAs can also function as
potential oncogenes or tumor suppressor genes, suggesting a direct
role in cancer initiation [13]; their role in metastasis, chemosensi-
tivity, and radiosensitivity has also been reported [14].
Furthermore, determining miRNA expression may have diagnostic
and prognostic value in pancreatic cancer [12] as dysregulated
miR-148a, miR-217, and miR-196a expression was observed in
the PDAC precursor, pancreatic entraepithelial neoplasm [15]. In
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tissues could be differentiated through the analysis of miR-217 and
miR-196a [10]. In PDAC patients, miR-155, miR-203, miR-210 and
miR-222 expression was signiﬁcantly associated with poorer
overall survival [11].
We previously identiﬁed miRNAs that were dysregulated in
pancreatic cancer, including miR-216a, miR-216b, miR-217,
miR-130b and miR-604 downregulation and miR-1246,
miR-517*, miR-146a, miR-645 and miR-424* upregulation [16].
Although downregulated miR-216a expression was correlated
with tumor T stage [16], its function in pancreatic cancer is
unknown. Therefore, the primary objective of the present study
was to explore the expression of miR-216a in pancreatic cancer
and its effect on pancreatic cell proliferation. These studies may
form the basis for identifying novel treatment strategies as well
as diagnostic or prognostic markers for pancreatic cancer.
2. Materials and methods
2.1. Tissue samples
Fourteen pancreatic ductal adenocarcinoma tissues (6 females
and 8 males of 44–78 y; mean age, 61 y) and six benign pancreatic
tissue lesions (3 females and 3 males of age 45–74 y; mean age
60 y) were obtained from patients undergoing pancreaticoduo-
denectomy at the Guangdong General Hospital from 2007 to
2009. Benign pancreatic tissue was selected in place of normal
adjacent tissue from cancer patients to prevent cancer tissue
contamination due to unclear borders. Among the six benign
pancreatic lesions, two were classiﬁed as chronic pancreatitis,
two were mucinous cystic neoplasms, one was a serous cystic neo-
plasm, and one was a solid pseudopapillary neoplasm. All tissue
samples were derived from untreated patients undergoing surgery,
and written informed consent was obtained before collection. This
study was approved by the Internal Review Board of the
Guangdong General Hospital, China.
All the samples were immediately snap-frozen in liquid nitro-
gen and stored at 80 C until analyzed Histopathologic analysis,
including hematoxylin and eosin staining, was performed by two
professional pathologists. Other clinical data were obtained from
the medical records at the Department of General Surgery of
Guangdong General Hospital.
2.2. Cell culture
The pancreatic adenocarcinoma cell line, PANC-1, was kindly
provided by the Biochip Department of the Guangdong General
Hospital obtained from the American Type Culture Collection
(ATCC) and was maintained in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM; Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Invitrogen), 100 units/mL penicillin and 100 lg/mL
streptomycin. Cells were cultured in a humidiﬁed incubator with
an atmosphere of 5% CO2 and 95% air at 37 C. Cells were tested
regularly for mycoplasma using the MycoProbe Mycoplasma
Detection Kit (Minneapolis, MN, USA).
The immortalized but not transformed pancreatic cell line,
HPDE6c7, was obtained from Kyushu University, and the pancre-
atic tumor cell lines, BxPC3, panc-1, CFPAC-1, and Aspc-1, were
all purchased from ATCC (Manassas, VA, USA). These cell lines were
cultured following the manufacturer’s instructions.
2.3. RNA extraction
Total RNA was extracted from the tissue samples using the
mirVana™ RNA Isolation Kit (Applied Biosystem, Ambion, TX,USA) following the manufacturer’s instructions. RNA concentra-
tions and quality were determined with 2100 Bioanalyzer
(Agilent, Santa Clara, CA, USA).
2.4. miRNA microarray
Microarray analysis was performed using 100 ng of total RNA
from histologically conﬁrmed pancreatic cancer tissues and benign
pancreatic lesions, and carried out using the Agilent HumanmiRNA
Microarray (V12.0) following the manufacturer’s instructions.
Brieﬂy, low-molecular weight RNA was dephosphorylated, dena-
tured, and labeled with Cyanine 3-pCp using T4 RNA ligase. After
hybridization for 20 h using the miRNA Complete Labeling and
Hyb Kit (Agilent) the array was washed twice with Gene
Expression Wash Buffers for 5 min each at 37 C. The microarray
was next scanned (Agilent), and the data was extracted using the
Agilent feature extraction software version 9.5.3 followed by
Quantile normalization using GeneSpring GX10.0 software
(Agilent).
2.5. qRT-PCR analysis
Total RNA extraction using Trizol and was puriﬁed by
chloroform extraction and dissolved in H2O. The lack of protein
contamination was conﬁrmed using a BioPhotometer plus UV/Vis
photometer (Eppendorf, Hauppauge, NY) as follows: OD260/
OD280 > 1.8. RNA integrity was conﬁrmed using agarose gel elec-
trophoresis. qRT-PCR analysis was undertaken in triplicate using
a SYBR Green qPCR SuperMix (Invitrogen) and an ABI PRISM
7500 Sequence Detection System with the following primers:
miR-216a (MIMAT0000273) forward, 50-TAATCTCAGCTGGCAACT
GTGA-30; miR-216a reverse, 50-TCACAGTTGCCAGCTGAGATTA-30
or 50-CTCAACTGGTGTCGTGGA-30 (for validation experiments in
ASPC-1, PANC, Capanc, and Bxp3, and HPDE6-c7 cell lines.); U6 for-
ward, 50-CTCGCTTCGGCAGCACA-30 and U6 reverse, 50-AACGCTTC
ACGAATTTGCGT-30. The following cycling conditions were used:
95 C for 5 min; 40 cycles of 95 C for 15 s, 65 C for 15 s and
72 C for 32 s; and melting curve analysis from 60 C to 95 C.
The relative expression was calculated as follows: 2DDCt, in which
DDCt (tumor cell DCt-non-tumor cell DCt).
2.6. Plasmid construction
The putative miR-216a target sequence of the JAK2 30 untrans-
lated region (30-UTR) was 50-UGAGAUU-30, corresponding to
nucleotides 833–839, as predicted by miRanda (miRBase or micro-
rna.org [17]), TargetScanS [18], and PicTar [19]. The human JAK2
30-UTR, which corresponded to the miR-216a binding site (NCBI
access number MI0000292), was ampliﬁed by RT-PCR using the
following primers (target site is underlined; Invitrogen,
Guangzhou, China):
JAK2XhoIF, 50-CCGCTCGAGAAGAAATGACCTTCATTCTGAGATT-
A-30 and JAK2NotIR, 50-AAGGAAAAAAGCGGCCGCTAAAGTAAGAAA
CTATTTTCTTTTTAATCAAAAC-30. The human JAK2 30-UTR contain-
ing mutated miR-216a-binding sites was generated using the fol-
lowing primers (mutated target site is underlined; Invitrogen):
mutJAK2F, mutJAK2F: 50 GAACAGTTTTCTTTTAAAATTTATCGATCAA
GAATGCCAGGAATATTGTC30 and mutJAK2R: 50 GACAATATTCCTGG
CATTCTTGATCGATAAATTTTAAAAGAAAACTGTTC 30.
The ampliﬁed products were cloned into the PsiCHECK™-2 vec-
tor (Promega, Madison, WI, USA).
miR-216a mimics (MIMAT0000273; UAAUCUCAGCUGGCAACU
GUGA) and miR-216a inhibitor, in which the complementary
strand was methylated, were synthesized by RiboBio
(Guangzhou, China). siRNA duplexes containing non-speciﬁc
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All of the constructs were conﬁrmed by sequencing (Invitrogen).
2.7. Cell transfection
PANC-1 cells (2  104)were seeded in triplicatewells of a 24-well
plate and maintained in RPMI1640 (Invitrogen) with 10% FBS 24 h
prior to transfection. At 50–60% conﬂuence, the cells were washed
with PBS and maintained in 300 lL OPTI-MEM (Invitrogen) with
an atmosphere of 5% CO2 and 95% air at 37 C. Cells were cotrans-
fected with 0.5 lg of psiCHECK2-JAK2, psiCHECK2-mut JAK2 or
psiCHECK2 together with 1 lL miR-216a mimics, miR-216a inhibi-
tor, NC or NC inhibitor with 1 lL Lipofectamine 2000 Reagent
(Invitrogen) according to the manufacturer’s instructions. PANC-1
cells were cultured for 5 h at 37 C in a humidiﬁed incubator with
5% CO2 atmosphere after which the transfection medium was
replaced with fresh medium supplemented with 10% FBS.
2.8. Luciferase assay
At 48 h following transfection, PANC-1 cells were rinsed twice
with PBS and lysed with 100 lL Passive Lysis Buffer for 15 min
and harvested. Fireﬂy and Renilla luciferase activities were mea-
sured using the GloMaxTM 20/20 Dual-Luciferase Reporter assay
system (Promega). Fireﬂy luciferase activity was normalized to
Renilla luciferase activity.
2.9. Western blot analysis
After cultivation under standard conditions described above for
24 h, PANC-1 cells that were transfected with miR-216a mimics or
an miR-216a inhibitor were harvested, and whole-cell protein was
isolated using RIPA lysis buffer (Santa Cruz Biotechnology,
sc-24948) according to the manufacturer’s instructions. Protein
concentrations were determined using the BCA method, and
100 lg of protein was separated by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE) and transferred to a
PVDF membrane (MILLIPORE, IPVH00010). After the membranes
were incubated in blocking buffer consisting of Tris buffered saline
(TBS), 0.1% Tween 20, and 5% non-fat dry milk for 1 h at room tem-
perature, they were incubated with rabbit polyclonal antibodies
speciﬁc for JAK2 (1:5000 dilution; Bioworld Technology,
Minneapolis, MN, USA) at 4 C overnight. After three washes in
TBS/0.1% Tween 20, the membranes were incubated with goat
anti-rabbit IgG secondary antibody (1:20000 dilution; Southern
Biotech, Birmingham, AL, USA) and an horseradish peroxidase
(HRP)-conjugated glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) antibody (1:10000 dilution; Kangcheng Biotech,
Shanghai, China) for 1 h at room temperature. After three washes
in TBS/0.1% Tween 20, reactions were detected using the
Immobilon Western Chemiluminescent HRP Substrate (Millipore,
Billerica, MA, USA).
2.10. Establishment of PANC-1 xenografts in nude mice
Eighteen SPF grade female BALB/C nude mice (4–6 weeks old)
were purchased from the Guangdong Medical Laboratory Animal
Center. All animals were maintained in an animal room for at least
3 days to adjust to the environment. The use of animals in this
study complies with the Guide for the Care and Use of
Laboratory Animals (NIH publication No. 86–23, revised 1985)
and the current Chinese regulations and standards on the use of
Laboratory Animals.
PANC-1 cells in log phase growth were harvested by trypsin
digestion and adjusted to a concentration of 5  107 cells/mL;0.1 mL was subcutaneously inoculated at the right back ﬂank.
When the tumors were visible, tumor size was measured with a
caliper for the length and the width and calculated using the fol-
lowing formula: V = 0.5  length width2. When the tumor size
reached P50 mm3 (after approximately 2 weeks), the
tumor-bearing nude mice were randomized into the following
three groups with six mice per group: PBS control, miR-216a ago-
mir, and NC agomir groups. Treatments consisting of 0.1 mL PBS
control, miR-216a agomir, or NC agomir were administered by
direct injection into the tumor at days 1, 4, 7, and 10. After tumor
volumes were measured at day 13, mice were sacriﬁced by cervical
dislocation, and the tumors were harvested for subsequent TUNEL
and immunohistochemical analysis.
2.11. Preparation of parafﬁn-embedded tumor tissue
After the tumor tissues were ﬁxed with 4% paraformaldehyde
for 24–36 h, sections of 0.2 cm thickness were obtained and incu-
bated in 70%, 80%, 90% and 95% ethanol (60 min per incubation).
The sections were next incubated in 100% ethanol two times for
1 h each, followed by a 1:1 xylene:anhydrous ethanol solution
and two washes in xylene (15 min each). Tissues were next embed-
ded in parafﬁn at 60 C twice for 60 min each.
2.12. Immunohistochemistry analysis
Tissue sections were deparafﬁnized in xylene twice and subse-
quently incubated in 100%, 95%, 85%, 75%, 50% ethanol and pure
water. After blocking endogenous peroxidase activity with 3%
H2O2 for 10 min at room temperature, antigen retrieval was under-
taken by boiling the sections in citrate antigen retrieval solution
(Guangzhou Leader Bio-Technology) for 8 min. The sections were
next blocked in 10% normal goat serum at room temperature for
30 min and incubated with antibodies speciﬁc for Ki67 (1:100)
and PCNA (1:200) (Guangzhou Leader Bio-Technology) at 4 C
overnight followed by secondary antibodies at room temperature
for 30 min and DAB staining according to the manufacturer’s pro-
tocol (ChemMate DAKO Envision Detection Kit Guangzhou Leader
Bio-Technology). After the tissue sections were counterstained
with hematoxylin and washed with water, they were incubated
in graded alcohol solutions and xylene and mounted.
2.13. Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) analysis
Tissue sections were deparafﬁnized in xylene twice and subse-
quently incubated in 100%, 95%, 85%, 75%, 50% ethanol and pure
water and rinsed with 0.85% NaCl for 5 min. According to the man-
ufacturer’s protocol (Guangzhou Leader Bio-Technology), sections
were next ﬁxed with 4% paraformaldehyde for 15 min, washed
twice with PBS, and incubated in 20 lg/mL proteinase K at room
temperature for 30 min. After washing twice with PBS, the sections
were ﬁxed with 4% paraformaldehyde for 10 min, washed twice
with PBS, and incubated in Equilibration Buffer at room tempera-
ture for 10 min. The sections were next incubated in rTdT reaction
buffer consisting of 98 lL Equilibration Buffer, 1 lL biotinylated
nucleotide mix, and 1 lL rTdT Enzyme at 37 C for 60 min. After
washing in 2X SSC buffer for 15 min and twice with PBS, the sec-
tions were incubated in 3% H2O2 at room temperature for
10 min, washed twice with PBS, and incubated in a Streptavidin
HRP solution at room temperature for 30 min. Sections were next
washed twice with PBS and stained with DAB. After the tissue sec-
tions were counterstained with hematoxylin and washed with
water, they were incubated in graded alcohol solutions and xylene
and mounted.
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Statistical analyses were performed using SPSS 15.0 statistics
software (SPSS Inc, Chicago, IL, USA). Data were represented as
mean with standard deviations (S.D.) for the given conditions.
The protein levels of miR-216a between malignant and benign
subjects were compared using two-sample t-tests. One-way
ANOVA with post hoc Bonferroni pair-wise comparisons was
applied to compare the difference among more than two groups.
All P-values <0.05 were considered signiﬁcant. Furthermore, an
adjusted signiﬁcance level of 0.01 and 0.0167 were applied for
assessments as multiple comparisons for ﬁve or three groups,
respectively.
3. Results
3.1. miR-216a is frequently downregulated in pancreatic cancer
To identify miRNAs potentially involved in pancreatic tumori-
genesis, we performed miRNA microarray proﬁling in 14 primary
pancreatic cancer tissues and six benign pancreatic lesions from
patients undergoing pancreaticoduodenectomy. A total of 70
miRNAs were differentially expressed (fold change ofP2), includ-
ing downregulation of 41 miRNAs and upregulation of 29 miRNAs,Table 1
Differential miRNA expression in pancreatic cancer tissues versus benign pancreatic lesion
Downregulated miRNAs
miRNA Fold-change (C vs. N) P-value
Has-miR-1234 2.034 >0.05
Has-miR-1203 2.042 <.001
Has-miR-30e 2.051 0.009
Has-miR-18b* 2.079 0.029
Has-miR-935 2.122 >0.05
Has-miR-875-5p 2.123 >0.05
Has-miR-767-3p 2.129 0.002
Has-miR-149* 2.134 0.024
Has-miR-190b 2.146 >0.05
Has-miR-506 2.147 >0.05
Has-miR-7g* 2.148 0.024
Has-miR-1236 2.153 0.017
Has-miR-30d 2.214 0.007
Has-miR-7b 2.313 >0.05
Has-miR-1915 2.325 >0.05
Has-miR-301b 2.421 >0.05
Has-miR-365 2.453 0.014
Has-miR-30d* 2.496 0.005
Has-miR-654-5p 2.562 0.015
Has-miR-628-3p 2.97 <0.001
Has-miR-28-3p 3.54 <.001
Has-miR-29c 3.632 0.012
Has-miR-338-3p 3.659 >0.05
Has-miR-30a 3.706 0.015
Has-miR-942 3.947 >0.05
Has-miR-219-5p 4.285 0.003
Has-miR-130b 4.588 0.001
Has-miR-604 4.738 0.001
Has-miR-30a* 4.999 0.018
Has-miR-939 5.119 <.001
Has-miR-564 5.383 0.001
Has-miR-141* 5.504 0.021
Has-miR-30b 5.76 0.045
Has-miR-130b 7.448 0.001
Has-miR-200c 7.815 >0.05
Has-miR-141 10.293 0.026
Has-miR-148a* 15.23 <.001
Has-miR-148a 15.6 <.001
Has-miR-216a 97.81 <.001
Has-miR-261b 117.473 >0.05
Has-miR-217 150.396 <.001in pancreatic cancer compared to benign pancreatic lesions by sig-
niﬁcance analysis of microarray (SAM; Table 1 and Fig. 1A).
Given that Szafranska et al. [10] identiﬁed miR-216 as a
pancreas-speciﬁc miRNA, we selected this particular miRNA for
further analysis. miR-216a was downregulated in more than 70%
of pancreatic cancer samples (10 of 14 samples) as compared with
the benign pancreatic lesions. RT-PCR analysis of the 14 tumor
samples and six benign samples conﬁrmed that miR-216a was sig-
niﬁcantly downregulated in pancreatic cancer as compared with
the benign pancreatic lesions (P < 0.001; Fig. 1B). The mean expres-
sion of miR-216a in the 14 pancreatic cancer tissues was 3.753
(S.D. = 2.705); the mean expression of miR-216a in the six benign
tissues was 10.276 (S.D. = 0.560). Finally, qRT-PCR analysis using
the pancreatic tumor cell lines, ASPC-1, PANC, Capanc, and Bxp3,
vs. a non-tumor cell line, HPDE6-c7, conﬁrmed the reduced
expression of miR-216a in all of the tumor cell lines analyzed as
compared to non-tumor HPDE6-c7 cells (all P < 0.001; Fig. 1C).
3.2. Prediction and screening of miR-216a target genes
To investigate the possible role of dysregulated miR-216a
expression in pancreatic carcinogenesis, we employed miRanda
[17], TargetScanS [18], and PicTar [19] to identify putative
miR-216a gene targets. The selection criterion applied selects.
Upregulated miRNAs
miRNA Fold-change (C vs. N) P-value
Has-miR-124 2.075 >0.05
Has-miR-1276 2.13 0.043
Has-miR-505 2.184 >0.05
Has-miR-505* 2.191 0.007
Has-miR-1270 2.258 0.023
Has-miR-1538 2.272 0.015
Has-miR-128 2.282 0.029
Has-miR-1266 2.314 0.029
Has-miR-541 2.328 0.015
Has-miR-220c 2.331 >0.05
Has-miR-615-3p 2.488 0.008
Has-miR-551b* 2.505 0.049
Has-miR-1301 2.525 >0.05
Has-miR-431* 2.528 0.043
Has-miR-1304 2.554 0.01
Has-miR-593 2.669 0.008
Has-miR-1250 2.689 0.007
Has-miR-219-2-3p 2.723 >0.05
Has-miR-300 2.783 0.029
Has-miR-383 2.834 0.005
Has-miR-433 2.996 0.012
Has-miR-1255b 2.996 0.023
Has-miR-658 3.064 0.02
Has-miR-520a-5p 3.11 0.013
Has-miR-1246 4.244 0.001
Has-miR-424* 4.791 0.004
Has-miR-517* 4.821 0.001
Has-miR-146a 5.491 0.008
Has-miR-645 5.685 0.005
Fig. 1. miRNA microarray analysis in pancreatic cancer tissues and benign
pancreatic lesions. (A) Cluster analysis of miRNA expression in pancreatic cancer
tissues (p006, p011, p026, p032, p039, p051, p004, p013, p016, p020, p029, p034,
p050, and p085) and in benign pancreatic lesions (p003, p063, p024, p067, p054,
and p055). (B) Expression of miR-216a in pancreatic cancer tissues from 14 patients
and benign pancreatic lesions from six patients. Data were represented as
mean ± S.D. for malignant and benign patients and compared using two-sample t-
test. (C) qRT-PCR analysis of miR216a in the pancreatic tumor cell lines, ASPC-1,
PANC, Capanc, and Bxp3, and a non-tumor cell line, HPDE6-c7. The relative
expression was calculated as follows: 2DDCt, in whichDDCt (tumor cellDCt-non-
tumor cell DCt). Data were presented as mean ± S.D. for each cell line. Differences
were compared using a one-sample t-test as setting mean = 1 (for non-tumor cell
line). ***P < 0.001, as compared to the non-tumor cell line.
Fig. 2. JAK2 is a miR-216a target as detected by TargetScan. Alignments of
nucleotides 833–839 in the JAK2 30-UTR (red) with miR-216a (green), and the
mutation in the miR-216a-binding site of JAK2-mut (blue).
Fig. 3. Ectopic expression of miR-216a reduces JAK2 protein level in vitro. PANC-1
cells were transfected with either miR-216a mimics or a miR-216a inhibitor, and
JAK2 protein levels were determined by Western blot analysis with the indicated
antibodies. The level of GAPDH was used as a loading control. JAK2 protein levels
were represented as mean ± S.D. and compared using one-way ANOVA with a post
hoc Bonferroni test. ***,P < 0.001, indicates a signiﬁcant difference as compared
with PANC-1 cells alone or with a miR-216a inhibitor, respectively.
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genes predicted by at least two of the programs were accepted;
(ii) only putative target genes with a role in cell proliferation
and/or apoptosis and in at least one known cell signaling pathway
were selected; and (iii) only putative target genes that are known
to affect downstream signaling events directly were selected. As
predicted by both TargetScan and miRanda, the JAK2 gene was
identiﬁed as a potential miR-216a target with a PicTar score of2.33 that met all of the selection criteria; a potential
has-miR-216a target site was found at position 833–839 of the
JAK2 30UTR (Fig. 2).
3.3. JAK2 is a miR-216a target gene
To validate whether JAK2 is a miR-216a target, JAK2 protein
expression was determined in PANC-1 cells after overexpression
of miR-216a. As shown in Fig. 3, miR216a mimics signiﬁcantly
reduced the protein level of JAK2 (P < 0.001). Conversely, JAK2 pro-
tein expression was signiﬁcantly upregulated in PANC-1 cells
expressing a miR-216a inhibitor (P < 0.001).
miRNAs disturb the steady-state expression of target genes
through translational repression, mRNA cleavage and transcrip-
tional silencing. The consequences of miRNA expression depend
upon the degree of complementarity between the miRNA and the
target gene. Most animal miRNAs that contain central regions
which are non-complementary to their targets suppress the trans-
lation of the target mRNA [210–213]. To verify whether the pre-
dicted miR-216a-binding sites in the 30-UTR of JAK2 were
responsible for its regulation, we subcloned this region into a luci-
ferase reporter vector (PsiCHECK2-30-UTR JAK2). As shown in Fig. 4,
co-transfection of PsiCHECK2-30-UTR JAK2 with miR-216a mimics
into PANC-1 cells signiﬁcantly decreased the luciferase activity as
compared with the negative control miRNA and the PBS control
(both P = 0.01). Conversely, cotransfection of PANC-1 cells with
PsiCHECK2-30-UTR JAK2 and miR-216a inhibitor signiﬁcantly
increased luciferase activity (P < 0.01). No such changes in
Fig. 4. Inhibition of JAK2 expression by miR-216a interaction with its 30UTR.
Luciferase activity of the JAK2 30UTR reporter (JAK2), a mutant JAK2 30UTR reporter
(mut JAK2–1), and empty vector control (psi-CHECK2) after treatment with PBS, a
negative control (NC) miRNA, a NC inhibitor, miR-216a, and a miR-216a inhibitor.
(n = 3 for each experiment group; each sample was assayed in triplicate.) Data were
represented mean ± S.D. and compared using one-way ANOVA with a post hoc
Bonferroni test. *,P < 0.0167, signiﬁcantly different from the *JAK2 and mut JAK2–1
reporter activities; a–dP < 0.01, signiﬁcantly different from the aPBS, bNC, cNC
inhibitor, or dmiR-216a treatment groups.
Fig. 5. Treatment of PANC-1 tumors with miR-216a reduces JAK2 protein levels
in vivo. (A) qRT-PCR of miR-216a levels and (B) JAK protein levels in PANC-1 tumors
treated with PBS, negative control miRNA, and miR-216a. Data were presented as
mean ± S.D. by group and compared using one-way ANOVA with post hoc
Bonferroni test. Representative Western blot images for two tumors are shown in
the bottom panel. *,P < 0.0167, indicates a signiﬁcant difference from the *PBS and 
NC groups.
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(mutJAK2) and the vector control (psi-CHECK2). Moreover, of the
groups expressing the miR-216a inhibitor, the luciferase activity
in the JAK2 group was signiﬁcantly higher than that of the mut
JAK2-1 and psi-CHECK2 groups (P < 0.0167). Taken together, these
data indicated that JAK2 is a miR-216a target in PANC-1 pancreatic
cancer cells.
3.4. miR-216a expression reduced in vivo JAK2 protein expression in
PANC-1 tumors
To determine if treatment with miR-216a could inhibit JAK2
protein expression in vivo, PANC-1 xenografts were established in
nude mice and were treated with PBS, NC miRNA and miR-216a.
As shown in Fig. 5A, qRT-PCR analysis revealed thatmiR-216a levels
were signiﬁcantly higher in those PANC-1 tumors treated with
miR-216a (P < 0.001). In addition, signiﬁcantly reduced JAK2 pro-
tein levels were observed in PANC-1 tumors treated with
miR-216a as compared to the PBS and NC groups (P < 0.001).
3.5. In vivo miR-216a expression decreased tumor volume by
increasing tumor cell apoptosis and decreasing cell proliferation
The effects of miR-216a treatment on PANC-1 tumor volume
were next assessed. As shown in Fig. 6A, miR-216a signiﬁcantly
inhibited tumor volume at day 10 as compared to the PBS control
group (135.11 ± 15.53 vs. 187.85 ± 54.38 mm3, respectively;
P < 0.0167). At day 13, the miR-216a treatment group had signiﬁ-
cantly reduced tumor volume as compared to the PBS andNCgroups
(146.36 ± 11.41 vs. 264.90 ± 70.92 and 269.39 ± 52.26 mm3, respec-
tively; P < 0.0167).
We next determined whether the effect of miR-216a on tumor
volume was mediated by tumor cell apoptosis and proliferation. As
shown in Fig. 6B, the apoptosis rate of PANC-1 tumors was signif-
icantly greater in the miR-216a group as compared to the PBS and
NC groups (70.5% vs. 22.5% and 21.4%, respectively; P < 0.001).
Furthermore, immunohistochemical analysis revealed signiﬁcant
inhibition of Ki67 and PCNA cell proliferation markers in the
PANC-1 tumors (P < 0.0167; Fig. 6C and D, respectively). Taken
together, these results suggest that miR-216a decreased PANC-1
tumor volume by increasing apoptosis and decreasing cell
proliferation.4. Discussion
Pancreatic cancer is an aggressive malignancy characterized by
poor prognosis. Although aberrant expression of miRNAs in pan-
creatic cancer has been reported [12,14], few studies have eluci-
dated the role of speciﬁc miRNAs in pancreatic carcinogenesis. In
the present study, miRNA microarray analysis identiﬁed 70
miRNAs with altered expression in pancreatic cancer tissue as
compared to benign pancreatic lesions and focused on analyzing
miR-216a in detail. JAK2 was subsequently identiﬁed as a target
gene that was downregulated by miR-216a. Moreover, treatment
of PANC-1 cell tumors with miR-216a reduced tumor volume
through increasing tumor cell apoptosis and decreasing
proliferation.
Fig. 6. miR-216a inhibits PANC-1 tumor growth in vivo. (A) Tumor volume (n = 6 per group), (B) apoptosis rate by TUNEL (n = 6 per group), (C) Ki67 protein level by
immunohistochemistry (n = 6 per group), and (D) PCNA protein level by immunohistochemistry (n = 6 per group) were determined in PANC-1 tumors treated with PBS, NC
miRNA, and miR-216a. Data were presented as mean ± S.D. and compared using one-way ANOVA with post hoc Bonferroni test. *,P < 0.0167, indicates a signiﬁcant difference
from the *PBS and NC groups. IOD, integrated optic density.
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than 70% of pancreatic cancer samples as compared with the
benign pancreatic lesions. The downregulation of miR-216a in pan-
creatic tumors observed in the present study is consistent with
previous studies. For example, Szafranska et al. [10] found that
miR-216 was downregulated more than 200-fold in PDAC samples
as compared to normal tissue; a similar downregulation of
miR-216 was not observed in chronic pancreatitis samples.
Similarly, upon activation of pancreatic stellate cells to
myoﬁbroblast-like cells, a key step in pancreatic cancer progres-
sion, miR126 levels were downregulated [20]. Moreover, the
downregulation of miR-126 was associated with PDAC migration,
invasion and epithelial-to-mesenchymal transition and, therefore,
pancreatic cancer progression [21]. However, miR-216a expression
was not associated with PDAC patient survival [11].
Because little is known regarding the molecular targets of
miR-216a in pancreatic cancer, we sought to identify possible gene
targets that have a role in cell proliferation and/or apoptosis as
well as cell signaling. In our study, we conﬁrmed that JAK2 is a
miR-216a target. To our knowledge, JAK2 may be the ﬁrst target
gene identiﬁed to date that may be involved in the regulation of
carcinogenesis by miR-216a. Downregulation of miR-216a in pan-
creatic cancer may result in JAK2 overexpression and/or aberrant
activation, which could exacerbate the development of pancreatic
cancer. Although miR-216a inhibited PANC-1 tumor volume possi-
bly through inducing apoptosis and inhibiting cell proliferation,
further studies will determine if these effects are mediated at least
in part through targeting JAK2.
Previous studies have demonstrated that the JAK/STAT pathway
may play an important role in pancreatic cancer [4–7]. This path-
way transmits signals from the cell membrane to the nucleus in
response to extracellular growth factors and cytokines [22–26],regulating a number of pathways important in tumorigenesis,
including cell cycle progression, apoptosis, tumor angiogenesis,
invasion and metastasis, and tumor cell evasion of the immune
system [27]. For example, the JAK/STAT pathway induces the
expression of Bcl-xL, c-myc, IL-10, and PRAD-1 [28,29], and the con-
tinuous activation of JAK2 by missense mutation at the V617F site
has been detected in patients with polycythemia vera, essential
thrombocythemia and primary myeloﬁbrosis [30–32]. Although
constitutively active JAK2 has not been identiﬁed in pancreatic
cancer to date [33], constitutive activation of STATs, especially
STAT-3, has been detected in human tumors and cancer cell lines,
including blood malignancies and solid tumors [34].
Blocking the JAK/STAT3 pathway has emerged as an attractive
strategy for novel drug development [35], and phase II and III clin-
ical trials are currently underway to assess lestaurtinib, a multitar-
geted tyrosine kinase inhibitor, in acute myeloid leukemia [36]. In
addition, preclinical studies of Guggulsterone in pancreatic cancer
cells have revealed its anti-proliferative effects via inhibiting the
JAK/STAT signaling pathway [37]. Furthermore, cucurbitacin B
induced pancreatic cancer cell apoptosis via modulating the
JAK/STAT pathway [38]. Along with small molecule inhibitors of
JAK/STAT2 signaling, downregulation of JAK2 by either miR-216a
overexpression or RNAi may represent another therapeutic
approach to block this signaling pathway. Indeed, studies analyz-
ing the therapeutic potential of miRNAs have yielded encouraging
results. For example, the development of modiﬁed miRNA mole-
cules with longer a half-life and higher efﬁciency in vivo, such as
locked nucleic acid-modiﬁed oligonucleotides and the antisense
oligonucleotides termed ‘antagomirs’, have produced favorable
antitumor outcomes in experimental models [39]. Although direct
injection of miR-216a mimics into PANC-1 tumors reduced their
volume and miR-216 is a known apoptosis-related miRNA [40],
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tial of increasing miR-216a levels in pancreatic cancer. In addition,
given the restriction of miR-216 expression to normal pancreatic
tissue and its ability to predict chemosensitivity in colorectal can-
cer [41], its diagnostic potential requires further analysis as well
[15,42,43].
The present study has some limitations that warrant further
discussion. For example, the expression of miR-216a was not cor-
related with patient clinicopathological characteristics. This will
be performed in further studies with a larger number of patient
samples as well as a panel of PDAC cell lines. In addition, the role
of JAK2 in mediating the reduced tumor volume after miR-216a
treatment was not evaluated; therefore, further studies will deter-
mine if these effects are mediated at least in part through targeting
JAK2. Furthermore, although we chose to analyze JAK2 given its
role in cell proliferation and apoptosis, other miR-216a targets,
including y box-binding-1 (YB-1) [44,45], CD44 [46], and protein
kinase C alpha (PKCa) [47], will be analyzed in further studies.
Given that an inverse correlation between insulin growth factor
(IGF) activation and miR-216 levels was observed in hepatocellular
carcinoma [48], further studies will analyze the effects of miR-216
on IGF signaling molecules. Finally, we did not use laser capture
microdissection (LCM) for the isolation of the RNA in the present
study. Given that many pancreatic tumors are comprised of a
diverse population of cells, further studies will employ LCM.
5. Conclusion
miR-216a is frequently down-regulated in pancreatic cancer
cell and may function as a tumor suppressor to inhibit pancreatic
cancer cell proliferation potentially by downregulating JAK2.
Further studies with a larger number of patient samples are neces-
sary to fully explore the diagnostic and therapeutic potential of
miR-216a for pancreatic cancer.
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